Cancer/Tumor Profiling Market

Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025

Report Code: MD 4803 Jul, 2020, by marketsandmarkets.com

[302 Pages Report] The global cancer/tumor profiling market size is projected to reach USD 13.9 billion by 2025 from USD 8.3 billion in 2020, at a CAGR of 10.9% during the forecast period. The increasing incidence of cancer across the globe and the growing use of biomarkers in tumor profiling are the primary growth drivers for this market. In addition, the increase in cancer research and funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market.

Also, the increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, the high capital investment required for biomarker discovery and the technical issues with sample collection and storage are the key factors restraining market growth to a certain extent.

Cancer/Tumor Profiling Market

Impact of Covid-19 on the cancer/tumor profiling market in the forecast period (2020-2025)

The cancer/tumor profiling market is not expected to be significantly impacted by the COVID-19 pandemic in 2020-2021. Due to the COVID-19 outbreak, there has been a significant drop in cancer testing and diagnosis due to measures and resources implemented towards coronavirus. However, several patients affected with COVID-19 were people with malignancies, due to which cancer has been identified as a risk factor for COVID-19. Research in this area is further undertaken to understand the dynamics of the infection better, which is expected to propel the cancer research field further. On the other hand, we are estimating that the major share of tumor diagnostic and prognostic testing of cancer, along with personalized medicine, will grow at a stable pace in the next five years. There is a huge deferment of treatment schedule of surgeries, radiation therapy, and chemotherapy sessions. Hence, the cancer treatment of surgeries, radiation therapy, and chemotherapy sessions should come to the levels of 2019 by the first quarter of 2021.

Drivers, Restraints, Opportunities, and Challenges in the Cancer/Tumor Profiling Market (2020-2025)

Driver: Increasing incidence of cancer

Rise in cancer incidences is one of the major contributors to market growth in the overall cancer/tumor profiling market. The increasing burden of cancer can be attributed to several factors, including population growth and aging, as well as the changing prevalence of certain causes of cancer linked to social and economic development.

Restraint: Technical issues in sample collection and storage in the cancer/tumor profiling market

Sample collection is one of the key issues faced by service providers, followed by access to these samples. Stringent quality control of these samples is required, and they need to be stored under the right conditions to avoid any loss.

Opportunity: Increasing demand for personalized medicine

Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing the way many diseases are identified, classified, and treated. These advancements are particularly evident in the area of oncology.

Challenge: Poor regulatory and reimbursement scenario

Technological advancements have enhanced the development and use of tumor profiling technologies to identify the key attributes of a patient’s disease at an early stage and thus guide the selection of the therapy to benefit a particular patient. The acceptance of biomarker-based tests in clinical applications requires evidence of the biomarker’s clinical validity and utility. This is important not just only to help physicians in the decision-making process but also to achieve regulatory approvals and reimbursements for tests. However, amassing the data necessary to show clinical validity and utility may be a time-consuming and expensive process, which is further complicated by the lack of standard regulations.

Cancer/Tumor Profiling Market Interconnections

The immunoassays segment is expected to account for the largest share of the market, by technology, in 2019

Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share in 2019. These assays are used as a gold standard to conduct tumor profiling on a large scale as they help measure the presence and concentration of analytes in a sample. These tests are used for cancer diagnosis, prognosis, and treatment decisions. Moreover, the information gained by these tests in clinical settings helps shorten hospital stays and decrease the severity of illnesses by identifying and assessing the progression of the disease, leading to improved therapeutic choices.

The lung cancer segment is expected to grow at the highest CAGR during the forecast period

Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. In 2019, the breast cancer segment accounted for the largest share of the cancer/tumor profiling market, followed by lung cancer. The high prevalence of breast cancer across the globe is the major factor contributing to the large share of this segment. However, the lung cancer segment is expected to register the highest during the forecast period. The increasing incidence of lung cancer worldwide and the rising need for early diagnosis are supporting the growth of this segment.

The protein biomarker segment is expected to grow at the highest CAGR during the forecast period

Based on biomarker type, the cancer/tumor profiling market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. In 2019, the genetic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process. On the other hand, the protein biomarkers segment is estimated to grow at the highest CAGR during the forecast period majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase the enormous potential for directing personalized cancer therapy and treatment monitoring.

Research to account for the largest share of the market, by application, in 2019

Based on applications, the cancer/tumor profiling market is segmented into research and clinical applications. The research applications segment accounted for the largest share of the cancer/tumor profiling market in 2019. The large share of this segment is attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the growing funding for cancer research is propelling the growth of the market.

Cancer/Tumor Profiling Market By Region

The APAC market is expected to grow at the highest CAGR during the forecast period

The cancer/tumor profiling market in the Asia Pacific is expected to witness the highest CAGR during the forecast period. Factors such as the high incidence of cancer, growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics are expected to drive the growth of this market during the forecast period.

Key Market Players

The prominent players in the Cancer/Tumor Profiling Market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Diagnostics (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq(US), Histogene X (Belgium).

Illumina is a molecular diagnostics company engaged in the development, manufacturing, and marketing of integrated systems for the analysis of genetic variations and biological functions. The company offers a wide range of integrated sequencing and microarray systems, consumables, and analysis tools to accelerate and simplify genetic analysis. The company operates under two units—Product Revenue and Services & Other Revenue. The Product Revenue unit consists of consumables and instruments revenue, while the Services and Other Revenue unit consists of sequencing, genotyping, and instrument service contract revenue.

Scope of the Report:

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Technology, Cancer Type, Biomarker Type, Application and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Diagnostics (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq(US), Histogene X (Belgium).
 

The research report categorizes the market into the following segments and subsegments:

Cancer/Tumor Profiling Market, by Technology

  • COVID Impact on the Market, By Technology
  • Immunoassays
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Mass Spectrometry
  • In-Situ Hybridization
  • Microarrays
  • Others 

Cancer/Tumor Profiling Market, by Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Other Cancer 

Cancer/Tumor Profiling Market by Biomarker Type

  • Genomic Biomarker
  • Protein Biomarker 

Cancer/Tumor Profiling Market by Application

  • COVID Impact on the Market
  • Research
  • Biomarker Discovery
  • Personalized Medicine
  • Clinical Application
  • Diagnostics
  • Prognostics
  • Screening
  • Treatment & Monitoring 

Cancer/Tumor Profiling Market, by Region

  • COVID Impact on the Market
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
  • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In 2020, Illumina’s COVID response: Illumina partnered with IDbyDNA Partner to deliver NGS Infectious Disease solutions. The partnership aims to accelerate NGS’ adoption of clinical infectious disease testing. This partnership also aims to make next-generation software with powerful bioinformatics software that can turn data into actionable insights.
  • In 2018, Illumina acquired Edico Genome, a leading provider of data analysis acceleration solutions for NGS, to accelerate genomic data analysis.
  • In 2018, Illumina signed an agreement to acquire Pacific Biosciences to integrate Pacific’s sequencing solutions into the company and expand its offering of integrated workflows.
  • In 2017, Illumina opened its Solutions Center in the Genopole Campus in France as a customer-training center to support the development of skills for the expanding genomics industry in the country.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
1INTRODUCTION (PAGE NO 36)
1.1Objectives of the Study
1.2Market Definition & Scope
1.2.1Markets covered
Figure 1Cancer/tumor profiling market
1.2.2Years considered for the study
1.3Currency
1.4Stakeholders
1.5Limitations
1.6Summary of Changes
2RESEARCH METHODOLOGY (PAGE NO 40)
2.1Research Approach
Figure 2Research design
2.1.1Secondary research
2.1.1.1Key data from secondary sources
2.1.2Primary research
2.1.2.1Key data from primary sources
2.1.2.2Breakdown of primaries
Figure 3Breakdown of primary interviews: By company type, designation, and region
2.1.2.3Key industry insights
2.2Market Sizing & Validation Approach
Figure 4Segmental share analysis illustration
Figure 5Top-down approach
2.3Data Triangulation Approach
Figure 6Data triangulation methodology
2.4Assumptions for The Study
3EXECUTIVE SUMMARY (PAGE NO 49)
Figure 7Cancer/tumor profiling market, by technology, 2020 vs. 2025 (USD Million)
Figure 8Cancer/tumor profiling market, by cancer type, 2020 vs. 2025 (USD Million)
Figure 9Cancer/tumor profiling market, by biomarker type, 2020 vs. 2025 (USD Million)
Figure 10Cancer/tumor profiling market, by application, 2020 vs. 2025 (USD Million)
Figure 11Geographical snapshot of the cancer/tumor profiling market
4PREMIUM INSIGHTS (PAGE NO 54)
4.1Cancer/Tumor Profiling: Market Overview
Figure 12Increasing demand for personalized medicine to drive market growth
4.2Cancer/Tumor Profiling Market: Geographic Growth Opportunities
Figure 13China to register the fastest growth in the cancer/ tumor profiling market during the forecast period
4.3Regional Mix: Cancer/Tumor Profiling Market (2020–2025)
Figure 14APAC to witness the fastest growth during the forecast period (2020–2025)
4.4Cancer/Tumor Profiling Market: Developed Vs. Developing Markets (2020 Vs. 2025)
Figure 15Developing markets to register a higher growth rate between 2020 & 2025
5MARKET OVERVIEW (PAGE NO 58)
5.1Introduction
5.2Market Dynamics
Figure 16Cancer/tumor profiling market: drivers, restraints, opportunities, and challenges
5.2.1Market drivers
5.2.1.1Increasing incidence of cancer
Figure 17Global cancer incidence, 2008–2030
5.2.1.2Increasing use of biomarkers in cancer profiling
5.2.1.3Increasing cancer research and funding
5.2.1.4Technological advancements
Table 1Market drivers: impact analysis
5.2.2Market restraints
5.2.2.1High capital investment
5.2.2.2Technical issues with sample collection and storage
Table 2Market restraints: impact analysis
5.2.3Market opportunities
5.2.3.1Increasing demand for personalized medicine
Figure 18Launch of personalized medicine products, 2008–2016
5.2.3.2Growing need for point-of-care diagnostics
Table 3Market opportunities: impact analysis
5.2.4Market challenges
5.2.4.1Low biomarker discovery-to-approval ratio
5.2.4.2Poor regulatory and reimbursement scenario
Table 4Market challenges: impact analysis
6INDUSTRY INSIGHTS (PAGE NO 67)
6.1Introduction
6.2Industry Trends
Figure 19Increasing use of integrated omics data and growing focus on liquid biopsy tests are key market trends
6.2.1Integration of omics data
6.2.2Advances in liquid biopsy
6.2.3Organoids for personalized medicine
6.3COVID-19 Impact on The Cancer/Tumor Profiling Market
Figure 20Impact of COVID-19 on the cancer/tumor profiling market
7CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY (PAGE NO 71)
7.1Introduction
7.2COVID-19 Impact, by Technology
Figure 21Immunoassays to dominate the cancer/tumor profiling market during the forecast period
Table 5Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 6Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
7.3Immunoassays
7.3.1Immunoassay tests identify and assess the progression of disease, thereby providing information vital for better therapeutic choices
Table 7Cancer/tumor profiling market for immunoassays, by country/region, 2017–2019 (USD Million)
Table 8Cancer/tumor profiling market for immunoassays, by country/region, 2020–2025 (USD Million)
7.4Next Generation Sequencing
7.4.1Advances in ngs multiplexing capabilities enable one assay to provide a complete tumor molecular profile
Table 9Cancer/tumor profiling market for next generation sequencing, by country/region, 2017–2019 (USD Million)
Table 10Cancer/tumor profiling market for next generation sequencing, by country/region, 2020–2025 (USD Million)
7.5Polymerase Chain Reaction
7.5.1Real-time pcr helps in the quantification of low-copy transcripts, aiding biomarker identification
Table 11Cancer/tumor profiling market for polymerase chain reaction, by country/region, 2017–2019 (USD Million)
Table 12Cancer/tumor profiling market for polymerase chain reaction, by country/region, 2020–2025 (USD Million)
7.6In Situ Hybridization
7.6.1Fish is the gold standard for evaluating some key biomarkers and plays a critical role in guiding targeted therapies
Table 13Cancer/tumor profiling market for in situ hybridization, by country/region, 2017–2019 (USD Million)
Table 14Cancer/tumor profiling market for in situ hybridization, by country/region, 2020–2025 (USD Million)
7.7Microarrays
7.7.1Microarrays are widely adopted in diagnostics as they aid in predicting the recurrence of cancer after treatment
Table 15Cancer/tumor profiling market for microarrays, by country/region, 2017–2019 (USD Million)
Table 16Cancer/tumor profiling market for microarrays, by country/region, 2020–2025 (USD Million)
7.8Mass Spectrometry
7.8.1Technological advancements are supporting the adoption of this technology for sensitive, reliable, and rapid diagnosis
Table 17Cancer/tumor profiling market for mass spectrometry, by country/region, 2017–2019 (USD Million)
Table 18Cancer/tumor profiling market for mass spectrometry, by country/region, 2020–2025 (USD Million)
7.9Other Technologies
Table 19Cancer/tumor profiling market for other technologies, by country/region, 2017–2019 (USD Million)
Table 20Cancer/tumor profiling market for other technologies, by country/region, 2020–2025 (USD Million)
8CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE (PAGE NO 90)
8.1Introduction
Figure 22Breast cancer segment to dominate the cancer/tumor profiling market during the forecast period
Table 21Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 22Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
8.2Breast Cancer
8.2.1Breast cancer is the most common cancer found among women
Table 23Cancer/tumor profiling market for breast cancer, by country/region, 2017–2019 (USD Million)
Table 24Cancer/tumor profiling market for breast cancer, by country/region, 2020–2025 (USD Million)
8.3Lung Cancer
8.3.1Molecular characterization of tumors using ngs is a key tool for the clinical management of nsclc patients
Figure 23Global lung cancer incidence, 2012-2030
Table 25Cancer/tumor profiling market for lung cancer, by country/region, 2017–2019 (USD Million)
Table 26Cancer/tumor profiling market for lung cancer, by country/region, 2020–2025 (USD Million)
8.4Colorectal Cancer
8.4.1IHC, PCR, microarrays, and imaging technologies are major technologies used in colorectal diagnostics
Figure 24Colorectal cancer incidence rate, key countries (2018)
Table 27Cancer/tumor profiling market for colorectal cancer, by country/region, 2017–2019 (USD Million)
Table 28Cancer/tumor profiling market for colorectal cancer, by country/region, 2020–2025 (USD Million)
8.5Prostate Cancer
8.5.1Prostate-specific antigen is a widely used fda-approved biomarker for prostate cancer screening
Table 29Cancer/tumor profiling market for prostate cancer, by country/region, 2017–2019 (USD Million)
Table 30 Cancer/tumor profiling market for prostate cancer, by country/region, 2020–2025 (USD Million)
8.6Melanoma
8.6.1RT-QPCR is generally utilized to conduct molecular profiling and analyze biomarkers in melanomas
Table 31Cancer/tumor profiling market for melanoma, by country/region, 2017–2019 (USD Million)
Table 32Cancer/tumor profiling market for melanoma, by country/region, 2020–2025 (USD Million)
8.7Other Cancers
Table 33Cancer/tumor profiling market for other cancers, by country/region, 2017–2019 (USD Million)
Table 34Cancer/tumor profiling market for other cancers, by country/region, 2020–2025 (USD Million)
9CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE (PAGE NO 107)
9.1Introduction
Figure 25Genetic biomarkers to dominate the cancer/tumor profiling market during the forecast period
Table 35Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 36Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
9.2Genetic Biomarkers
9.2.1Genetic biomarkers are frequently used in clinical practice for diagnosis and prognosis
Table 37Cancer/tumor profiling market for genetic biomarkers, by country/region, 2017–2019 (USD Million)
Table 38cancer/tumor profiling market for genetic biomarkers, by country/region, 2020-2025 (USD Million)
9.3Protein Biomarkers
9.3.1Proteomic methods showcase significant promise for the discovery of novel biomarkers
Table 39Cancer/tumor profiling market for protein biomarkers, by country/region, 2017–2019 (USD Million)
Table 40Cancer/tumor profiling market for protein biomarkers, by country/region, 2020–2025 (USD Million)
9.4Other Biomarkers
Table 41Cancer/tumor profiling market for other biomarkers, by country/region, 2017–2019 (USD Million)
Table 42Cancer/tumor profiling market for other biomarkers, by country/region, 2020–2025 (USD Million)
10CANCER/TUMOR PROFILING MARKET, BY APPLICATION (PAGE NO 116)
10.1Introduction
10.2COVID-19 Impact, by Application
Figure 26Research applications to dominate the cancer/tumor profiling market during the forecast period
Table 43Cancer/tumor profiling market, by application, 2017–2019 (USD Million)
Table 44Cancer/tumor profiling market, by application, 2020–2025 (USD Million)
10.3Research Applications
Table 45Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 46Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
10.3.1Biomarker discovery
10.3.1.1Biomarkers are being exploited for the development of personalized or precision medicine
Table 47Cancer/tumor profiling market for biomarker discovery, by country/region, 2017–2019 (USD Million)
Table 48Cancer/tumor profiling market for biomarker discovery, by country/region, 2020–2025 (USD Million)
10.3.2Personalized medicine
10.3.2.1The field of personalized medicine is witnessing rapid growth in the area of oncology
Table 49Cancer/tumor profiling market for personalized medicine, by country/region, 2017–2019 (USD Million)
Table 50Cancer/tumor profiling market for personalized medicine, by country/region, 2020–2025 (USD Million)
10.4Clinical Applications
Table 51Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 52Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
10.4.1Diagnostics
10.4.1.1Tumor profiling is rapidly gaining momentum in the area of diagnostics
Table 53Cancer/tumor profiling market for diagnostics, by country/region, 2017–2019 (USD Million)
Table 54Cancer/tumor profiling market for diagnostics, by country/region, 2020–2025 (USD Million)
10.4.2Prognostics
10.4.2.1Advancements in molecular biology are aiding the uptake of tumor profiling in this segment
Table 55Cancer/tumor profiling market for prognostics, by country/region, 2017–2019 (USD Million)
Table 56Cancer/tumor profiling market for prognostics, by country/region, 2020–2025 (USD Million)
10.4.3Monitoring & treatment
10.4.3.1Multiplatform profiling analyses are gaining recognition for monitoring and treatment among cancer patients
Table 57Cancer/tumor profiling market for monitoring & treatment, by country/region, 2017–2019 (USD Million)
Table 58Cancer/tumor profiling market for monitoring & treatment, by country/region, 2020–2025 (USD Million)
10.4.4Screening
10.4.4.1Screening tests help in deciding if diagnostic tests are required by the patient
Table 59Cancer/tumor profiling market for screening, by country/region, 2017–2019 (USD Million)
Table 60Cancer/tumor profiling market for screening, by country/region, 2020–2025 (USD Million)
11CANCER/TUMOR PROFILING MARKET, BY REGION
11.1Introduction
11.2COVID-19 Impact, by Region
Figure 27Cancer/tumor profiling market: geographic snapshot
Table 61Cancer/tumor profiling market, by region, 2017–2019 (USD Million)
Table 62Cancer/tumor profiling market, by region, 2020–2025 (USD Million)
11.3North America
Figure 28North America: Cancer/tumor profiling market snapshot
Table 63North America: Cancer/tumor profiling market, by country, 2017–2019 (USD Million)
Table 64North America: Cancer/tumor profiling market, by country, 2020–2025 (USD Million)
Table 65North America: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 66North America: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 67North America: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 68North America: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 69North America: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 70North America: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 71North America: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 72North America: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 73North America: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 74North America: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.3.1US
11.3.1.1US dominates the North American cancer/tumor profiling market
Table 75US: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 76US: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 77US: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 78US: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 79US: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 80US: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 81US: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 82US: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 83US: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 84US: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.3.2Canada
11.3.2.1Growing public-private partnerships to promote proteomics research are expected to drive the market in Canada
Table 85Canada: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 86Canada: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 87Canada: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 88Canada: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 89Canada: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 90Canada: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 91Canada: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 92Canada: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 93Canada: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 94Canada: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.4Europe
Figure 29Europe: Cancer/tumor profiling market snapshot
Table 95Europe: Cancer/tumor profiling market, by country, 2017–2019 (USD Million)
Table 96Europe: Cancer/tumor profiling market, by country, 2020–2025 (USD Million)
Table 97Europe: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 98Europe: Cancer/tumor profiling market, by technology,2020–2025 (USD Million)
Table 99Europe: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 100Europe: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 101Europe: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 102Europe: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 103Europe: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 104Europe: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 105Europe: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 106Europe: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.4.1Germany
11.4.1.1Advancements in proteomics and genomics research are expected to drive market growth
Table 107Germany: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 108Germany: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 109Germany: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 110Germany: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 111Germany: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 112Germany: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 113Germany: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 114Germany: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 115Germany: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 116Germany: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.4.2UK
11.4.2.1Growth in the life sciences industry and the increase in academia-industry partnerships will be the key factors driving the market
Table 117UK: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 118UK: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 119UK: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 120UK: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 121UK: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 122UK: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 123UK: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 124UK: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 125UK: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 126UK: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.4.3France
11.4.3.1Growth in this market is primarily driven by increasing investments in life science R&D for infrastructural development
Table 127France: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 128France: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 129France: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 130France: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 131France: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 132France: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 133France: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 134France: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 135France: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 136France: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.4.4Italy
11.4.4.1Increasing investment in cancer and translational research is expected to propel market growth during the forecast period
Table 137Italy: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 138Italy: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 139Italy: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 140Italy: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 141Italy: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 142Italy: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 143Italy: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 144Italy: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 145Italy: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 146Italy: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.4.5Spain
11.4.5.1Rising incidence of cancer and increasing focus on cancer biomarkers by various medical societies to support market growth in Spain
Table 147Spain: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 148Spain: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 149Spain: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 150Spain: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 151Spain: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 152Spain: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 153Spain: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 154Spain: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 155Spain: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 156Spain: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.4.6Rest of Europe
Table 157Rest of Europe: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 158Rest of Europe: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 159Rest of Europe: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 160Rest of Europe: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 161Rest of Europe: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 162Rest of Europe: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 163Rest of Europe: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 164Rest of Europe: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 165Rest of Europe: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 166Rest of Europe: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.5Asia Pacific
Figure 30Asia Pacific: Cancer/tumor profiling market snapshot
Table 167Asia Pacific: Cancer/tumor profiling market, by country, 2017–2019 (USD Million)
Table 168Asia Pacific: Cancer/tumor profiling market, by country, 2020–2025 (USD Million)
Table 169Asia Pacific: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 170Asia Pacific: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 171Asia Pacific: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 172Asia Pacific: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 173Asia Pacific: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 174Asia Pacific: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 175Asia Pacific: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 176Asia Pacific: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 177Asia Pacific: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 178Asia Pacific: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.5.1Japan
11.5.1.1Large number of research initiatives towards the development of precision medicine supporting market growth in Japan
Table 179Japan: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 180Japan: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 181Japan: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 182Japan: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 183Japan: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 184Japan: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 185Japan: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 186Japan: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 187Japan: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 188Japan: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.5.2China
11.5.2.1China has the fastest-growing research sector in the APAC region
Table 189China: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 190China: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 191China: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 192China: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 193China: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 194China: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 195China: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 196China: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 197China: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 198China: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.5.3India
11.5.3.1Increasing pharma R&D and government funding in the biotechnology industry are the major factors driving market growth in India
Table 199India: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 200India: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 201India: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 202India: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 203India: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 204India: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 205India: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 206India: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 207India: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 208India: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.5.4Rest of Asia Pacific
Table 209Rest of Asia Pacific: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 210Rest of Asia Pacific: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 211Rest of Asia Pacific: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 212Rest of Asia Pacific: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 213Rest of Asia Pacific: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 214Rest of Asia Pacific: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 215Rest of Asia Pacific: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 216Rest of Asia Pacific: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 217Rest of Asia Pacific: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 218Rest of Asia Pacific: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.6Latin America
11.6.1Growing proteomics research in the field of cancer along with the rising use of advanced techniques to drive market growth
Table 219Latin America: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 220Latin America: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 221Latin America: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 222Latin America: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 223Latin America: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 224Latin America: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 225Latin America: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 226Latin America: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 227Latin America: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 228Latin America: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
11.7Middle East & Africa
11.7.1Growing genomics and proteomics research and increasing research collaborations are expected to support market growth
Table 229Middle East: Cancer/tumor profiling market, by technology, 2017–2019 (USD Million)
Table 230Middle East: Cancer/tumor profiling market, by technology, 2020–2025 (USD Million)
Table 231Middle East: Cancer/tumor profiling market, by cancer type, 2017–2019 (USD Million)
Table 232Middle East: Cancer/tumor profiling market, by cancer type, 2020–2025 (USD Million)
Table 233Middle East: Cancer/tumor profiling market, by biomarker type, 2017–2019 (USD Million)
Table 234Middle East: Cancer/tumor profiling market, by biomarker type, 2020–2025 (USD Million)
Table 235Middle East: Cancer/tumor profiling market for research applications, by type, 2017–2019 (USD Million)
Table 236Middle East: Cancer/tumor profiling market for research applications, by type, 2020–2025 (USD Million)
Table 237Middle East: Cancer/tumor profiling market for clinical applications, by type, 2017–2019 (USD Million)
Table 238Middle East: Cancer/tumor profiling market for clinical applications, by type, 2020–2025 (USD Million)
12COMPETITIVE LANDSCAPE (PAGE NO 224)
12.1Overview
Figure 31Collaborations, partnerships, and agreements—key growth strategy adopted by market players from 2016 to april 2020
12.2Competitive Leadership Mapping
12.2.1Visionary leaders
12.2.2Innovators
12.2.3Dynamic differentiators
12.2.4Emerging companies
Figure 32Cancer/tumor profiling market: competitive leadership mapping (2018)
12.3Competitive Situation And Trends
12.3.1Product launches, approvals, and enhancements
Table 239Product launches, 2016–2020
12.3.2Expansions
Table 240Expansions, 2016–2020
12.3.3Acquisitions
Table 241Acquisitions, 2016–2020
12.3.4Other strategies
Table 242Other strategies, 2016–2020
13COMPANY PROFILES (PAGE NO 231)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1ILLUMINA, INC.
Figure 33ILLUMINA, INC.: Company snapshot (2019)
13.2QIAGEN N.V.
Figure 34QIAGEN N.V.: Company snapshot (2019)
13.3NEOGENOMICS, INC.
Figure 35NEOGENOMICS, INC.: Company snapshot (2019)
13.4SYSMEX CORPORATION
Figure 36SYSMEX CORPORATION: Company snapshot (2019)
13.5HTG MOLECULAR DIAGNOSTICS, INC.
Figure 37HTG MOLECULAR DIAGNOSTICS, INC.: Company snapshot (2019)
13.6HELOMICS CORPORATION
13.7CARIS LIFE SCIENCES
13.8NANOSTRING TECHNOLOGIES, INC.
Figure 38NANOSTRING TECHNOLOGIES, INC.: Company snapshot (2019)
13.9RIBOMED BIOTECHNOLOGIES, INC.
13.10GUARDANT HEALTH, INC.
Figure 39GUARDANT HEALTH, INC.: Company snapshot (2019)
13.11FOUNDATION MEDICINE
13.12F. HOFFMANN-LA ROCHE LTD
Figure 40F. HOFFMANN-LA ROCHE LTD: Company snapshot (2019)
13.13GENSCRIPT BIOTECH CORPORATION
Figure 41GENSCRIPT: Company snapshot (2019)
13.14TEMPUS LABS
13.15HISTOGENE X
13.16Other Companies
13.16.1HOLOGIC, INC.
13.16.2BOREAL GENOMICS INC
13.16.3PERTHERA
13.16.4AGENDIA
13.16.5OMNISEQ
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
14APPENDIX (PAGE NO 293)
14.1Insights of Industry Experts
14.2Discussion Guide
14.3knowledge Store: Marketsandmarkets’ Subscription Portal
14.4Available Customizations
14.5Related Reports
14.6Author Details

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of widespread secondary sources; directories; databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers; annual reports; and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of global cancer/tumor profiling market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, key developments related to market, and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in cancer/tumor profiling market. The primary sources from the demand side include industry experts such as surgeons, physicians and doctors, and life science researchers.

A breakdown of the primary respondents is provided below:

Cancer/Tumor Profiling Market Size

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by technology, by cancer type, by biomarker type, application, and region).

Data Triangulation

After arriving at the market size, cancer/tumor profiling market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, segment, and forecast cancer/tumor profiling market by product, indication, application, end user, and region
  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to overall cancer/tumor profiling market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of cancer/tumor profiling market in five main regions along with their respective key countries, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players in cancer/tumor profiling market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as acquisitions; new product launches; expansions; collaborations, agreements, and partnerships; and R&D activities of the leading players in cancer/tumor profiling market
  • To benchmark players within cancer/tumor profiling market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Geographic Analysis

  • A further breakdown of the Latin American cancer/tumor profiling market into Brazil, Mexico, and the Rest of Latin America
  • A further breakdown of European cancer/tumor profiling market into Switzerland, Netherlands, and the Rest of Europe.
COVID-19

Get in-depth analysis of the COVID-19 impact on the Cancer/Tumor Profiling Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Cancer/Tumor Profiling Market

Request For Special Pricing
Report Code
MD 4803
Published ON
Jul, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cancer/Tumor Profiling Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home